

P

Pharmaceuticals

Ms Jennie Butler
Dockets Management Branch
(HFA-305)
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

Welwyn, June 13, 2000

Dear Ms Butler,

FDA Public meeting on regulation of OTC products 28-29 June 2000

Further to your email of 9th June 2000, I would like formally register my interest to attend the above meeting.

Participants name; Helen C Jackson PhD (Clinical Scientist)

Address; Clinical Science Department, Roche Global Development, Roche Products Ltd, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, UK

Telephone number; 44 1707 365870

Affiliation; Roche Products Ltd

The organization paying travel expenses; Roche Products Ltd

Question for the Agency; Please can the Agency comment on the criteria that would make a drug suitable for nurse-prescribing and clarify whether these criteria differ from those required of an OTC medication.

Thank you for your assistance,

Yours sincerely,

Dr. Helen Jackson
Roche Products Limited

00N-1256

Roche Products Ltd

40 Broadwater Road
Welwyn Garden City
Hertfordshire AL7 3AY U.K.
Registered No.

Pharma Development
PDC-2 Clinical Science
B50/1 Albany Place

Tel. +44 (0)1707 365870
Fax +44 (0)1707 365887
Internet:
helen.jackson@roche.com

APE 72